• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Suggested Reading: Which insulin should I choose now that my options have dwindled?

May 1, 2006
David S. Bruyette, DVM, DACVIM

On Dec. 31, 2005, Eli Lilly discontinued four of its insulin products: Humulin L Lente insulin, Humulin U Ultralente insulin, Regular Iletin II pork insulin, and NPH Iletin II pork insulin. Our challenges are to switch patients currently receiving these products to comparable insulin preparations and to change our treatment approach in newly diagnosed diabetes mellitus cases.

On Dec. 31, 2005, Eli Lilly discontinued four of its insulin products: Humulin L Lente insulin, Humulin U Ultralente insulin, Regular Iletin II pork insulin, and NPH Iletin II pork insulin. Our challenges are to switch patients currently receiving these products to comparable insulin preparations and to change our treatment approach in newly diagnosed diabetes mellitus cases. Here are some suggested guidelines I use in my hospital.

David S. Bruyette, DVM, DACVIM (internal medicine)

Dogs

Newly diagnosed cases

1. Vetsulin (Intervet): This porcine-origin, zinc, lente insulin is intermediate-acting. Canine and porcine insulin have an identical amino acid sequence, which eliminates the theoretical complication of the dog developing anti-insulin antibodies that may adversely affect glycemic control. While the manufacturer recommends once-a-day initial dosing, I have not found this to be effective in most of our patients. I suggest an initial starting dose of 0.5 U/kg given subcutaneously twice a day. This insulin is available only at a concentration of 40 IU/ml, so make sure you provide U-40 insulin syringes to owners. Reassess the dog's clinical signs and perform a serial blood glucose curve one week after starting therapy.

2. Humulin N (Eli Lilly): This is an intermediate-acting, human-origin insulin. Suggested starting doses are 0.5 U/kg given subcutaneously twice a day. Reassess the dog's clinical signs and perform a serial blood glucose curve one week after starting therapy. The long-term availability of this product is uncertain.

Advertisement

A Few Words About Blood Glucose Monitoring

3. PZI insulin: This long-acting, protamine zinc, beef-pork-origin insulin has, in my experience, not been more effective in controlling clinical signs in dogs than intermediate-acting insulins. This insulin is available only at a concentration of 40 IU/ml, so make sure you provide U-40 insulin syringes to owners. I recommend an initial starting dose of 0.5 U/kg given subcutaneously twice a day. If you select PZI insulin, I recommend that you use PZI Vet (Idexx), as compounded insulins can provide inconsistent treatment results. PZI is labeled for use in cats; for additional product information see the manufacturer's Web site: www.idexx.com.

4. Insulin glargine: To date, no information on the use of glargine in diabetic dogs is available (see the discussion below regarding insulin glargine and cats).

Changing insulin

In dogs receiving Humulin L Lente insulin, I recommend switching to either Vetsulin or Humulin N. The initial dose of Vetsulin or Humulin N will remain the same as the dose used with Humulin L, but be sure to reassess the dog's clinical signs and perform a serial blood glucose curve one week after changing insulin preparations.

Cats

Newly diagnosed cases

1. Insulin glargine (Lantus—Aventis): This is a modified, recombinant, long-acting insulin analogue approved for use in people. A study presented at the American College of Veterinary Internal Medicine annual meeting in 2005 showed a high rate of remission (8/8 in remission within four months, with 6/7 still in remission at one year) in feline diabetics with the use of glargine and a low-carbohydrate, high-protein diet. The recommended starting dose is 0.5 U/kg given subcutaneously twice a day if the fasting blood glucose concentration is greater than 360 mg/dl, or 0.25 U/kg given subcutaneously twice a day if the initial fasting blood glucose concentration is less than 360 mg/dl.1-3

2. PZI insulin: As with dogs, I recommend using PZI Vet. The initial starting dose is 1 to 3 U/cat given subcutaneously once a day.4 However, in my experience, most cats will need twice-a-day administration. In my experience, remission rates are 40% to 50% within three or four months of starting treatment when this insulin is used in conjunction with a low-carbohydrate, high-protein diet.

3. Humulin N (Eli Lilly): In my experience, remission rates are 40% to 50% when this insulin is used with a low-carbohydrate, high-protein diet. Starting doses are generally 1 to 3 U/cat given subcutaneously twice a day.

4. Vetsulin (Intervet): I have seen remission rates of 40% to 50% when this insulin is used with a low-carbohydrate, high-protein diet in cats. Starting doses are generally 1 to 3 U/cat given subcutaneously twice a day.5 This product is not approved for use in cats.

Changing insulin

In cats that are receiving either Humulin L Lente or Humulin U Ultralente, I recommend switching to either PZI Vet, Vetsulin, or Humulin N. The initial starting dose remains the same as stated above for newly diagnosed patients. Reassess the cat's clinical signs and perform a serial blood glucose curve one week after changing insulin preparations. If you wish to switch to glargine, follow the dosage recommendations as outlined above under newly diagnosed cases. Note that remission rates will be much lower with glargine and a low-carbohydrate, high-protein diet in long-standing diabetic patients (cats with diabetes for more than six months) than in patients in which diabetes has been newly diagnosed.

David S. Bruyette, DVM, DACVIM (internal medicine), is a Veterinary Medicine Editorial Advisory Board member and the medical director of VCA West Los Angeles Animal Hospital in Los Angeles, Calif.

REFERENCES

1. Marshall R, Rand J. Comparison of the pharmacokinetics and pharmacodynamics of glargine, protamine zinc, and porcine lente insulin in healthy cats, in Proceedings. Aust Coll Vet Scientists Sci Week 2003.

2. Stenner VJ, Fleeman LM, Rand JS. Comparison of the pharmacodynamics and pharmacokinetics of subcutaneous glargine, protamine zinc and lente insulin preparations in healthy dogs (abst). J Vet Intern Med 2004;18:444-445.

3. Marshall RD, Rand JS. Treatment with glargine results in higher remission rates than Lente or protamine zinc insulins in newly diagnosed diabetic cats (abst). J Vet Intern Med 2005;19:425.

4. Nelson RW, Lynn RC, Wagner-Mann CC, et al. Efficacy of protamine zinc insulin for treatment of diabetes mellitus in cats. J Am Vet Med Assoc 2001;218:38-42.

5. Martin GJ, Rand JS. Pharmacology of a 40 IU/ml porcine lente insulin preparation in diabetic cats: findings during the first week and after 5 or 9 weeks of therapy. J Feline Med Surg 2001;3:23-30.

Related Content:

Endocrinology
Dr Natalie Marks to lecture on diabetes management with Dr Adam Christman
Dr Natalie Marks to lecture on diabetes management with Dr Adam Christman
Top 3 pancreatic diseases in dogs
Top 3 pancreatic diseases in dogs
Hypoadrenocorticism in the emergency setting
Hypoadrenocorticism in the emergency setting

Advertisement

Latest News

An update on copper concerns in pet foods

Dental hacks to make every case more manageable

Q&A with a keynote: Walter Brown, RVTg, VTS, ECC

News wrap-up: This week’s headlines, plus dvm360® launches its first CE podcast

View More Latest News
Advertisement